These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21116237)

  • 1. Chemotherapy: maintenance rituximab for relapsed follicular lymphoma.
    Wrench D; Montoto S
    Nat Rev Clin Oncol; 2010 Dec; 7(12):677-8. PubMed ID: 21116237
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites.
    Hiroshima Y; Tajima K; Shiono Y; Suzuki I; Kouno K; Yamamoto M; Kato Y; Kato T
    Ann Hematol; 2012 Sep; 91(9):1499-500. PubMed ID: 22281990
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematology: Follicular lymphoma: maintenance therapy is (often) indicated.
    Seymour JF
    Nat Rev Clin Oncol; 2009 Nov; 6(11):624-6. PubMed ID: 19861993
    [No Abstract]   [Full Text] [Related]  

  • 5. A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma.
    Marcus R; Aultman R; Jost F
    Br J Cancer; 2010 Jan; 102(1):19-22. PubMed ID: 19920818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
    Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
    Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
    Gopal AK; Kahl BS; Flowers CR; Martin P; Ansell SM; Abella-Dominicis E; Koh B; Ye W; Barr PM; Salles GA; Friedberg JW
    Blood; 2017 Jun; 129(22):3037-3039. PubMed ID: 28325864
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
    van Oers MH; Van Glabbeke M; Giurgea L; Klasa R; Marcus RE; Wolf M; Kimby E; van t Veer M; Vranovsky A; Holte H; Hagenbeek A
    J Clin Oncol; 2010 Jun; 28(17):2853-8. PubMed ID: 20439641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma.
    Konishi T; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y
    Hematol Oncol; 2019 Aug; 37(3):303-307. PubMed ID: 30933366
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
    [No Abstract]   [Full Text] [Related]  

  • 11. Follicular lymphoma: 2012 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
    Palacios Abufón A; Acebo Mariñas E; Gardeazabal García J; García-Ruiz JC
    Actas Dermosifiliogr; 2012 Apr; 103(3):253-5. PubMed ID: 22093542
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab maintenance versus retreatment in follicular lymphoma.
    Palla AR; Hamadani M
    Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
    Lazzarino M; Arcaini L; Bernasconi P; Alessandrino EP; Gargantini L; Cairoli R; Orlandi E; Astori C; Brusamolino E; Pagnucco G; Colombo AA; Calatroni S; Iacona I; Regazzi MB; Morra E
    Br J Haematol; 2002 Jan; 116(1):229-35. PubMed ID: 11841421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive lymphoma: improving treatment outcome with rituximab.
    Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in management of follicular lymphoma].
    Zinzani PL
    Rinsho Ketsueki; 2014 Oct; 55(10):1937-40. PubMed ID: 25297758
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrospective study of the utility of FLIPI/FLIPI-2 for follicular lymphoma patients treated with R-CHOP.
    Numata A; Tomita N; Fujimaki K; Tanaka M; Hashimoto C; Oshima R; Matsumoto K; Matsuura S; Yamamoto W; Motomura S; Ishigatsubo Y
    J Clin Exp Hematop; 2012; 52(1):77-9. PubMed ID: 22706536
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
    Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M
    Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy.
    Kusano Y; Yokoyama M; Terui Y; Inoue N; Takahashi A; Yamauchi H; Tsuyama N; Nishimura N; Mishima Y; Takeuchi K; Hatake K
    Blood Cancer J; 2017 Sep; 7(9):e614. PubMed ID: 28960192
    [No Abstract]   [Full Text] [Related]  

  • 20. Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma.
    Derenzini E; Casadei B; Broccoli A; Gandolfi L; Pellegrini C; Zinzani PL
    Br J Haematol; 2014 Aug; 166(4):625-8. PubMed ID: 24750128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.